Delta Financial Advisors LLC Buys 4,830 Shares of AbbVie Inc. $ABBV

Delta Financial Advisors LLC lifted its holdings in AbbVie Inc. (NYSE:ABBV) by 225.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 6,971 shares of the company’s stock after buying an additional 4,830 shares during the period. Delta Financial Advisors LLC’s holdings in AbbVie were worth $1,614,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of ABBV. Evolution Wealth Management Inc. purchased a new stake in AbbVie during the 2nd quarter valued at approximately $26,000. Spurstone Advisory Services LLC purchased a new position in AbbVie in the second quarter worth about $28,000. Financial Gravity Companies Inc. bought a new position in shares of AbbVie during the 2nd quarter valued at approximately $36,000. Bear Mountain Capital Inc. lifted its stake in shares of AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after acquiring an additional 173 shares during the last quarter. Finally, Delos Wealth Advisors LLC bought a new position in AbbVie in the second quarter worth approximately $39,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ABBV shares. Erste Group Bank lowered AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Cantor Fitzgerald set a $250.00 price target on shares of AbbVie and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Bank of America upped their target price on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Finally, Piper Sandler reissued an “overweight” rating and set a $289.00 target price (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $248.11.

AbbVie Stock Up 0.5%

NYSE:ABBV opened at $219.21 on Friday. The company has a fifty day simple moving average of $225.60 and a two-hundred day simple moving average of $217.22. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The company has a market cap of $387.42 billion, a price-to-earnings ratio of 166.07, a price-to-earnings-growth ratio of 0.90 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the previous year, the firm earned $3.00 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is 524.24%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.